Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Svetlana Bergelson"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 341-346 (2020)
Recombinant adeno-associated virus (rAAV) is one of the main vectors used in gene therapy. An accurate genome titer is not only critical for clinical dosing, but also a prerequisite for many analytical assays for AAV product characterization. AAV gen
Externí odkaz:
https://doaj.org/article/92382db7fe5f4e9abea47ade33e7c29d
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss , Pp 526-531 (2019)
Recombinant adeno-associated virus (rAAV) is a vector with increasing popularity in the field of gene therapy. Like other drug substances manufactured in cell lines, rAAV vectors are commonly contaminated with host cell DNA, and the levels must be ca
Externí odkaz:
https://doaj.org/article/46007e7c9467439885611c3a325f07d2
Autor:
Allyson Kwiatkowski, Carl Co, Sei Kameoka, An Zhang, John Coughlin, Tom Cameron, Eric Chiao, Svetlana Bergelson, Cullen Schmid Mason
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
The terminal sugars of Fc glycans can influence the Fc-dependent biological activities of monoclonal antibody therapeutics. Afucosylated N-glycans have been shown to significantly alter binding to FcγRIIIa and affect antibody-dependent cell-mediated
Externí odkaz:
https://doaj.org/article/de7297e0eace436aacfb3a8b6386340a
Publikováno v:
The Scientific World Journal, Vol 1, Pp 96-96 (2001)
Externí odkaz:
https://doaj.org/article/2093f1a466d1457b943429766040d04e
Autor:
Ruth Frenkel, Dana Tribby, Boris Boumajny, Nicholas Larson, Matthew Sampson, Christopher Barney, Svetlana Bergelson, Zoran Sosic, Bernice Yeung
Publikováno v:
The AAPS journalReferences. 25(1)
The genome content of adeno-associated virus (AAV) vectors is critical to the safety and potency of AAV-based gene therapy products. Empty capsids are considered a product-related impurity and a critical quality attribute (CQA) of the drug product, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc63ef02717cc89ac12577413d8959dd
https://pubmed.ncbi.nlm.nih.gov/36414847
https://pubmed.ncbi.nlm.nih.gov/36414847
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Plaque assays are used to measure the infectious titer of viral samples. These assays are multi-day and low-throughput and may be subject to analyst variability from biased or subjective manual plaque counting. Typically, on day 1, cells are adhered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3f46cc5b38fea0cbe8368470bdb8c36
https://doi.org/10.1016/j.omtm.2019.07.007
https://doi.org/10.1016/j.omtm.2019.07.007
Autor:
Vinay Bhatt, Ryan Dickerson, Christopher Argento, John Pieracci, Meisam Bakhshayeshi, Xiaotong Fu, Xiaohui Lu, Peter Clarner, Svetlana Bergelson, George M. Bou-Assaf, Wei-Chiang Chen
Publikováno v:
Human Gene Therapy Methods. 30:144-152
Recombinant adeno-associated virus (rAAV)-mediated gene therapy is a fast-evolving field in the biotechnology industry. One of the major challenges in developing a purification process for AAV gene therapy is establishing an effective yet scalable me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371c8e875f01b80c96012c68505767e2
https://doi.org/10.1089/hgtb.2019.088
https://doi.org/10.1089/hgtb.2019.088
Publikováno v:
Cell and Gene Therapy Insights. 5:455-463
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d8bf67c2291194d29fef28913251757
https://doi.org/10.18609/cgti.2019.050
https://doi.org/10.18609/cgti.2019.050
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss, Pp 526-531 (2019)
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss, Pp 526-531 (2019)
Recombinant adeno-associated virus (rAAV) is a vector with increasing popularity in the field of gene therapy. Like other drug substances manufactured in cell lines, rAAV vectors are commonly contaminated with host cell DNA, and the levels must be ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b7aa4c801e4baf7ac85f4b6f2124e03
http://europepmc.org/articles/PMC6551374
http://europepmc.org/articles/PMC6551374
Autor:
John Coughlin, Allyson Kwiatkowski, Carl Co, Svetlana Bergelson, An Zhang, Cullen Schmid Mason, Eric Chiao, Sei Kameoka, Thomas Cameron
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The terminal sugars of Fc glycans can influence the Fc-dependent biological activities of monoclonal antibody therapeutics. Afucosylated N-glycans have been shown to significantly alter binding to FcγRIIIa and affect antibody-dependent cell-mediated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2583d749ae4e4fb41a919d528026d3
http://europepmc.org/articles/PMC7531570
http://europepmc.org/articles/PMC7531570